The economic burden of long COVID in Australia: more noise than signal?
Angeles, Mary Rose, Dinh, Thi Thu Ngan, Zhao, Ting et al. · The Medical journal of Australia · 2024 · DOI
Quick Summary
This Australian study looked at how many people have long COVID and how much it costs the economy. Researchers estimated that between 40,000 and 145,000 Australians were severely affected by long COVID in late 2022, costing the economy between $1.7 and $6.3 billion. The study found that tens of thousands of working-age Australians reported being unable to work due to long-term sickness, though Australia doesn't yet have good tracking systems to measure long COVID's true impact.
Why It Matters
This study is important because it demonstrates that long COVID and ME/CFS share similar functional impacts and economic consequences, providing evidence-based cost estimates that can inform healthcare policy and resource allocation. For ME/CFS patients, the study validates that severe post-viral illnesses create substantial documented economic hardship and work disability, supporting arguments for better recognition and support services.
Observed Findings
Between 181,000–682,000 Australians reported some long COVID symptoms at peak (late 2022), with 40,000–145,000 severely affected.
Severe case numbers declined to 10,000–38,000 by June 2023.
Labour market data showed 25,000–103,000 excess working-age Australians unable to work due to long-term sickness compared to pre-COVID trends.
Number of working-age Carer Allowance recipients increased markedly from 2022 onwards.
Long COVID's estimated economic burden was $1.7–$6.3 billion during 2022, representing 0.07–0.26% of GDP.
Inferred Conclusions
Long COVID imposed a small but measurable aggregate economic burden on Australia while causing substantial personal hardship for affected individuals.
The illness contributed to labour supply constraints in the working-age population.
Australia lacks adequate direct surveillance systems to reliably guide long COVID policy decisions.
Social security data suggests carer responsibilities from long COVID are under-recognized in disability benefit systems.
Remaining Questions
What is the true prevalence and severity of long COVID in Australia using direct clinical surveillance rather than modeled estimates?
What This Study Does Not Prove
This study does not definitively prove long COVID's actual economic impact due to reliance on proxy estimates from ME/CFS rather than direct long COVID cost data. The wide range of estimates (e.g., $1.7–$6.3 billion) reflects significant model uncertainty. The study cannot establish causation between long COVID and observed labour market changes, only associations with timing.
Tags
Symptom:Fatigue
Phenotype:Long COVID Overlap
Method Flag:Weak Case DefinitionNo ControlsExploratory Only
How do long COVID's economic and functional impacts actually compare to ME/CFS when measured in the same population?
Why did excess work disability from long COVID not translate into proportional increases in Disability Support Pension claims—are patients unable to access these benefits?
What proportion of long COVID cases progress to severe ME/CFS-like illness, and what are the long-term economic trajectories?